Role of trazodone in treatment of major depressive disorder: an update

A Fagiolini, A González-Pinto, KW Miskowiak… - Annals of general …, 2023 - Springer
Major depressive disorder (MDD) is the most common mood disorder and a leading cause
of disability worldwide. Trazodone, a triazolopyridine serotonin receptor antagonist and …

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

CB Eap, G Gründer, P Baumann… - The World Journal of …, 2021 - Taylor & Francis
Objectives: More than 40 drugs are available to treat affective disorders. Individual selection
of the optimal drug and dose is required to attain the highest possible efficacy and …

[HTML][HTML] Trazodone add-on in COVID-19-related selective serotonin reuptake inhibitor-resistant post-traumatic stress disorder in healthcare workers: two case reports

D De Berardis, M Fornaro, A Ventriglio… - Clinical …, 2021 - ncbi.nlm.nih.gov
COVID-19 represents a significant stress factor for all people worldwide due to several
factors, including quarantine, lockdowns, fear of contagion, deaths, and other traumatic …

[HTML][HTML] Update on pharmacological treatment for comorbid major depressive and alcohol use disorders: the role of extended-release trazodone

M Di Nicola, M Pepe, I Panaccione… - Current …, 2023 - ncbi.nlm.nih.gov
Background Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) are major
public health concerns because of their high prevalence and clinical and functional severity …

Chronic trazodone and citalopram treatments increase trophic factor and circadian rhythm gene expression in rat brain regions relevant for antidepressant efficacy

L Carboni, L Rullo, FF Caputi, S Stamatakos… - International Journal of …, 2022 - mdpi.com
Trazodone is an efficacious atypical antidepressant acting both as an SSRI and a 5HT2A
and 5HT2C antagonist. Antagonism to H1-histaminergic and alpha1-adrenergic receptors is …

Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use

A Cuomo, A Bianchetti, A Cagnin… - … of Gerontology and …, 2021 - usiena-air.unisi.it
Trazodone is indicated for the treatment of Major Depressive Disorder (MDD), often
associated with anxiety, insomnia, agitation, nervousness, or irritability. The aim of this …

[PDF][PDF] Leczenie farmakologiczne epizodu depresji i zaburzeń depresyjnych nawracających-wytyczne Polskiego Towarzystwa Psychiatrycznego i Konsultanta …

J Samochowiec, D Dudek, J Kucharska-Mazur… - Psychiatria …, 2021 - ruj.uj.edu.pl
Under the auspices of the Polish Psychiatric Association and the National Consultant in
Psychiatry, on the basis of analysis of international guidelines, the expert group consisting of …

Once-a-day trazodone in the treatment of depression in routine clinical practice

E Češková, M Šedová, R Kellnerová, O Starobová - Pharmacology, 2018 - karger.com
Objective: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a
day trazodone tablets (Trittico Prolong® 300 mg) in patients with moderate to severe …

Pharmacological treatment of a depressive episode and recurrent depressive disorder-guidelines of the Polish Psychiatric Association and the National Consultant for …

J Samochowiec, D Dudek… - Psychiatria …, 2021 - publicum.umed.lodz.pl
Under the auspices of the Polish Psychiatric Association and the National Consultant in
Psychiatry, on the basis of analysis of international guidelines, the expert group consisting of …

Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration

M Buoli, C Rovera, SM Pozzoli, A Fiorentini… - CNS …, 2019 - cambridge.org
ObjectiveSome antidepressants, such as trazodone or clomipramine, can be administered
intravenously in patients with major depressive disorder (MDD), with potential benefits …